JPMorgan Chase & Co. Has Lowered Expectations for Alphatec (NASDAQ:ATEC) Stock Price

Alphatec (NASDAQ:ATEC) had its target price reduced by investment analysts at JPMorgan Chase & Co. from $24.00 to $16.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 128.90% from the company’s current price.

Several other research firms also recently commented on ATEC. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research note on Friday, March 27th. TD Cowen decreased their price target on shares of Alphatec from $20.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Alphatec in a research note on Monday, January 12th. Needham & Company LLC decreased their price target on shares of Alphatec from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Lake Street Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Alphatec in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Alphatec Stock Down 31.7%

Shares of NASDAQ:ATEC traded down $3.24 during midday trading on Wednesday, reaching $6.99. The company had a trading volume of 21,562,737 shares, compared to its average volume of 3,222,331. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35. The business’s 50 day moving average price is $11.73 and its 200 day moving average price is $15.95. The stock has a market cap of $1.07 billion, a PE ratio of -7.36 and a beta of 0.96. Alphatec has a 1-year low of $6.85 and a 1-year high of $23.29.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.21). The company had revenue of $192.11 million during the quarter, compared to analyst estimates of $197.51 million. The business’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.35) earnings per share. Research analysts forecast that Alphatec will post -0.28 EPS for the current fiscal year.

Insider Activity

In other news, EVP David Sponsel sold 163,452 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $12.52, for a total value of $2,046,419.04. Following the completion of the transaction, the executive vice president owned 504,932 shares of the company’s stock, valued at approximately $6,321,748.64. This represents a 24.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the transaction, the general counsel directly owned 559,459 shares of the company’s stock, valued at $6,987,642.91. This trade represents a 13.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 689,614 shares of company stock valued at $8,634,850. Corporate insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Alphatec by 2.4% in the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock worth $99,091,000 after acquiring an additional 158,295 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Alphatec by 608.4% in the third quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after acquiring an additional 773,367 shares during the last quarter. Lisanti Capital Growth LLC bought a new position in shares of Alphatec in the third quarter worth about $3,305,000. Aberdeen Group plc lifted its holdings in shares of Alphatec by 29.7% in the fourth quarter. Aberdeen Group plc now owns 1,286,195 shares of the medical technology company’s stock worth $27,062,000 after acquiring an additional 294,792 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Alphatec in the third quarter worth about $1,115,000. Institutional investors own 66.35% of the company’s stock.

Key Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Q1 showed revenue growth (+13.6% YoY) with strong GAAP and non‑GAAP gross margins (~71–72%) and an improvement in EPS vs. last year — these operational improvements support longer‑term recovery prospects. ATEC Reports First Quarter Financial Results
• Positive Sentiment: Alphatec established a new senior secured syndicated credit facility to support growth and liquidity — this reduces short‑term financing risk. Alphatec Establishes New Syndicated Credit Facility for Growth
• Positive Sentiment: Sell‑side support remains: Needham and TD Cowen kept “buy” ratings despite lowering price targets, signaling analysts still see upside at current depressed levels. Analyst Coverage
• Neutral Sentiment: Company released the full earnings slide deck and the earnings call transcript — useful for digging into margin trends, customer dynamics, and the updated guidance assumptions. Q1 Slide Deck
• Negative Sentiment: Q1 EPS missed expectations: reported (‑$0.22) vs. consensus (‑$0.01) and revenue of $192.1M fell short of the ~$197.5M consensus — the earnings miss is a primary catalyst for the decline. Earnings Report Summary
• Negative Sentiment: Management trimmed its full‑year revenue outlook, triggering sharp investor re‑pricing and the immediate market reaction. Revenue Outlook Cut
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims against Alphatec executives — regulatory/litigation risk increases uncertainty and can pressure the stock. Johnson Fistel Investigation
• Negative Sentiment: Reported institutional selling (a fund disclosed ~$18M of sales last quarter), which contributes to added supply and downward pressure. Fund Selling Disclosed

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.